primary_duns:
824771034
Elm and Carlton Streets
Buffalo, NY 14263
United Stateshttps://www.roswellpark.org/shared-resources/flow-immune-analysiscite this facility
Orla Maguire
Last Updated: 04/04/2025
This state-of-the-art facility provides advanced flow cytometric and morphology services at cellular and subcellular levels of resolution. The services offered by the Flow and Immune Analysis Shared Resource (FIASR) include investigator access to equipment 24/7, education and consultation services, comprehensive sample processing, data acquisition and data analysis services, luminex cytokine, chemokine and growth factor quantification, and core flow cytometry services for investigator and biotech sponsored clinical trials.
is_active:
Yesbudget_end:
08/31/2025date_added:
09/07/2024agency_code:
NIHfiscal_year:
2024project_num:
5R50CA211108-08award_amount:
$342,107.00budget_start:
09/01/2024org_name:
ROSWELL PARK CANCER INSTITUTE CORPorg_state:
NYorg_country:
UNITED STATESorg_zipcode:
142630001primary_duns:
824771034abstract_text:
The current application seeks continued salary support for Hans Minderman, PhD who serves as the Associate Director of the Flow and Image Cytometry Shared Resource (FICSR) of the Roswell Park Comprehensive Cancer Center (Roswell Park). This position was created in 2007 to oversee the research applications of the various imaging (confocal, live cell imaging) and flow cytometry platforms available in the facility and to apply his extensive experience in these areas in collaborations and consultations with the FICSR investigator user base. With over 35 years of experience in clinical and research applications of flow and image cytometry (30 years at Roswell Park), Dr Minderman throughout his career has collaborated with many investigators at the Cancer Center on NIH funded projects. The FICSR is an integral part of Roswell Park’s Cancer Center Support grant (P30CA016056) for which the cancer center Director, Dr Johnson serves as the Principal Investigator. The Tumor Immunology & Immunotherapy (TII) CCSG program, previously co-led by the Unit Director on the original application, Dr Odunsi, is the major user base of the FICSR; but numerous NIH-funded researchers across all 5 CCSG programs actively collaborate and consult with Dr Minderman commensurate with the purpose of the PAR 21-286 funding opportunity. During his first R50 tenure (2016-2021), Dr Minderman’s contributions to Roswell Parks research enterprise have been significant and impactful specifically with regards to the NIH-funded research. As of October 2021, 137 extramural grant applications dependent on FICSR were awarded to Roswell Park faculty, 59 were awarded by NIH, 22 of which to members of the TII program. The cancer center has also made significant investments in the FICSR with the acquisition of a new confocal microscope, two spectral flow cytometry analyzers and a 3rd Fortessa analyzer. With the changes in the R50 program now making the distinction between Laboratory (PAR-20-288)- and Core (PAR-20-287)-based scientists and with the FICSR being an integral part of the Roswell Park CCSG infrastructure, Dr Johnson as the PI of the CCSG grant, will now serve as the Unit Director for the renewal application.project_title:
Associate-Director Flow and Image Cytometry Roswell Park ComprehensiveCancer Centercontact_pi_name:
MINDERMAN, HANStotal_cost:
$342,107.00is_active:
Nobudget_end:
06/30/2019date_added:
07/07/2018agency_code:
NIHfiscal_year:
2018project_num:
1S10OD025183-01award_amount:
$318,038.00budget_start:
07/01/2018org_name:
ROSWELL PARK CANCER INSTITUTE CORPorg_state:
NYorg_country:
UNITED STATESorg_zipcode:
142630001primary_duns:
824771034abstract_text:
Project Summary/Abstract Funds are requested for the purchase of a Sony SH800 cell sorter configured with 405, 488, 561 and 640 nm excitation lasers and fitted with a biocontainment enclosure. The requested instrument addresses the need for increased flow cytometry sorting capacity of the Flow and Image Cytometry Shared Resource (FICSR) at Roswell Park Cancer Institute. The requested equipment fulfills the need of a user-friendly sorting platform that can be self-operated without the need to schedule time with FICSR personnel. This increases flexibility of access to the sorting equipment which is important for the NIH-funded researchers since the sorting is usually an intermediary processing step between sample preparation and downstream sample analysis activities. The pre- and post-sort activities commonly are labor- and time-intensive and when dependent on clinical material, the sorts are difficult to rigorously schedule due to the logistics of surgery schedules which necessarily have to be flexible. Currently, the annual usage of the available sorting equipment at the FICSR exceeds 80% of capacity, and thus severely limits the availability of this service to NIH funded researchers. The decision on the specific sorter requested was based on a year-long evaluation that included the specific configuration needs for the NIH-funded user base, narrowing down the choice to 3 candidate instruments based on experiences of other flow cytometry core facilities nationwide and a final decision based on onsite demos of all three candidate instruments with potential users sorting and operating the sorters with their own samples.project_title:
Flow Cytometry Sortercontact_pi_name:
WALLACE, PAUL Ktotal_cost:
$318,038.00is_active:
Nobudget_end:
05/31/2015date_added:
06/07/2014agency_code:
NIHfiscal_year:
2014project_num:
1S10OD018048-01award_amount:
$399,500.00budget_start:
06/01/2014org_name:
ROSWELL PARK CANCER INSTITUTE CORPorg_state:
NYorg_country:
UNITED STATESorg_zipcode:
142630001primary_duns:
824771034abstract_text:
DESCRIPTION (provided by applicant): Funding is requested for an ImageStreamX-markII (ISX-MKII) imaging flow cytometer to replace a first generation ImageStream-100 cytometer. At the time of its commercial introduction in 2006, the IS-100 uniquely combined flow cytometry with quantitative image analysis. In anticipation of the applicability of this then novel platform or many of our NIH-funded users, the IS100 was acquired. The introduction of the ImageStream technology to our user group has been very successful leading to the award of 3 additional NIH-funded grants that rely heavily on this technology. Based on the success of implementing the IS100 at RPCI, the clear benefit of the technology to our research base and its high usage, an additional ImageStream, the ImageStreamX (ISX) was purchased as a second ImageStream platform with Institute support in 2009 and upgraded to the third generation ISX-MK-II in 2012. In addition, RPCI also invested in the expanded computational and data storage infrastructure and personnel needed in support of the increasing demand for this technology by the RPCI research base. The advanced ImageStream application demands of our user base enabled by the technological advancements implemented in the 3rd generation ISX-MKII have rendered the IS100 obsolete. Thus, the ISX-MK-II currently carries 100% of the work load and is operating at >80% capacity without a functional back up. The purchase of an additional ISX-MKII to replace the now obsolete IS100 will allow our facility to meet the increasing demand for advanced ImageStream applications and provide backup capability when the current machine is out-of-service due to maintenance or repair needs.project_title:
Imaging Flow Cytometercontact_pi_name:
MINDERMAN, HANStotal_cost:
$399,500.00is_active:
Nobudget_end:
04/30/2019date_added:
09/08/2018agency_code:
NIHfiscal_year:
2018project_num:
3P30CA016056-41S2award_amount:
$194,088.00budget_start:
05/01/2018org_name:
ROSWELL PARK CANCER INSTITUTE CORPorg_state:
NYorg_country:
UNITED STATESorg_zipcode:
142630001primary_duns:
824771034abstract_text:
DESCRIPTION (provided by applicant): Roswell Park Cancer Institute (RPCI) is an independent, free-standing research, education and clinical cancer care Institute. Dr. Donald Trump, CCSG PI and RPCI President/CEO, is responsible solely to the RPCI Board of Directors. RPCI has been continuously recognized as a Cancer Center since NCI first designated centers in 1974 and has been designated as a comprehensive center since that term was first employed. This application requests continued NCI support for another five years. RPCI occupies a 27 acre campus near downtown Buffalo. The RPCI campus consists of 1.6 million square feet (sf) of laboratory, office, clinical and education. An additional 142,000 sf clinical care, clinical research and office building began construction on April 18, 2013. New developments on the main campus since last review have included opening of the Centers for Immunotherapy, Robotic Surgery, and Personalized Medicine. An additional 16,000 sf of clinical space have been opened at three affiliate sites. While the population of the RPCI catchment area (the 8 county region of WNY from which ~86% of RPCI patients are drawn) has been generally stable at ~1.5M, the number of tumor registry cases has increased 25% since 2008. In 2012 RPCI physicians cared for 4,242 new tumor registry cases and a total of 8,626 new analytic and non-analytic cases. Since the last competitive renewal in 2008, RPCI has continued scientific, clinical, population science and education program growth, despite a difficult economic environment. This growth is demonstrated by: 1) recruitment of 137 new faculty clinicians and researchers, of which 51 are new CCSG members; 2) a 17% increase in total peer-reviewed funding from 2008 to 2013; 3) an increase in high-impact (impact factor>10) publications (91 to 193); 4) increased accrual to first-in-human, phase I, investigator-initiated studies; 24 accruals in 2008 vs 118 in 2012 and the highest phase I trial institutional recruitment in RPCI history; 5) 2.5X increase in the number of therapeutic (treatment) trials supported by peer-reviewed funding (27 to 67); and 6) opening of three new satellite RPCI facilities. RPCI has expanded its educational programs, including an international program for the training of cancer scientists, clinicians and administrators from around the world. RPCI has successfully recruited three Senior Leaders, and invested $277 million in resources for the future to build on RPCI's unique opportunities in experimental therapeutics, translational medicine, genomics and education.project_title:
Roswell Park Cancer Institute Cancer Center Support Grantcontact_pi_name:
JOHNSON, CANDACE Stotal_cost:
$194,088.00Services are offerred outside of
Consulting is offerred outside of
